Prostate cancer mortality among elderly men after discontinuing organised screening: Long-term results from the European randomised study of screening for prostate cancer Rotterdam
Niraparib with abiraterone acetate plus prednisone as first-line therapy in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: Three-year update and final analysis of MAGNITUDE
Refining risk stratification in patients undergoing radiotherapy and long-term ADT for high-risk/locally advanced prostate cancer: An individual patient dataanalysis of randomized controlled trials from the ICECaP consortium
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials
Can we rely on available models to identify candidates for extended Pelvic Lymph Node Dissection (ePLND) in men staged with PSMA-PET? External validation of the Briganti nomograms and development of a novel tool to identify optimal candidates for ePLND